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Immune function in the elderly is associated with a number of phenotypic and functional abnormalities, and
this phenomenon of immune senescence is associated with increased susceptibility to infection. The immune
response to pathogens frequently declines with age, but the CD8 T-cell response to cytomegalovirus (CMV)
is unusual, as it demonstrates a significant expansion over time. Here we have documented the CD4 T-cell
immune response to CMV in healthy donors of different ages. The magnitude of the CMV-specific CD4 T-cell
immune response increases from a mean of 2.2% of the CD4 T-cell pool in donors below 50 years of age to
4.7% in donors aged over 65 years. In addition, CMV-specific CD4 T cells in elderly donors demonstrate
decreased production of interleukin-2 and less dependence on costimulation. CMV seropositivity is associated
with marked changes in the phenotype of the overall CD4 T-cell repertoire in healthy aged donors, including
an increase in CD57 expression and a decrease in CD28 and CD27 expression, a phenotypic profile charac-
teristic of immune senescence. This memory inflation of CMV-specific CD4 T cells contributes to evidence
that CMV infection may be damaging to immune function in elderly individuals.
Healthy aging is associated with the development of a num-
ber of phenotypic and functional abnormalities of the immune
system. These include the accumulation of memory T cells,
impaired functional responses in vitro, and a reduction in the
response rate to vaccinations (5, 8). These findings are associ-
ated with the phenomenon of immune senescence and are
thought to underlie the increased rate of infectious disease that
is seen in elderly individuals (7).
The magnitude of the cellular immune response to a number
of pathogens has been studied in donors of different ages and
has revealed that cellular immunity to viruses such as influenza
virus and varicella-zoster virus decreases with advancing age
(3). In marked contrast to these findings, the CD8 T-cell re-
sponse to cytomegalovirus (CMV) increases markedly with
age, such that it may represent over 40% of the CD8 T-cell
pool (14, 15). A similar observation has been seen with the
CD8 T-cell immune response to murine cytomegalovirus (13).
There has been speculation that this accumulation of memory
CD8 T cells may itself contribute to features of immune se-
nescence, and this idea has gained support from studies of
elderly donors in whom CMV seropositivity is associated with
the development of an immunological phenotype associated
with impaired survival (16, 29).
CD4 T cells are important in the induction and regulation of
the cellular immune response to pathogens, and an impaired
CMV-specific CD4 T-cell immune response has been corre-
lated with prolonged viral secretion following neonatal infec-
tion (10). Currently little is known with regard to how the
magnitude or functional properties of the CD4 T-cell immune
response to CMV are influenced by aging. Here we have stud-
ied the CMV-specific CD4 T-cell response to CMV viral lysate
in a cohort of 30 young individuals aged less than 50 years and
compared this to 40 elderly individuals aged over 60 years. We
find that the CMV-specific immune response increases mark-
edly with age and leads to the development of phenotypic and
functional changes within the CD4 T-cell repertoire which
have previously been associated with immune senescence.
MATERIALS AND METHODS
Donors. Blood was taken from laboratory personnel or a cohort of healthy
elderly volunteers known as “The Thousand Elders.” Ethical permission was
obtained from the Local Ethical Committee for the study, and written consent
was obtained in all cases.
Blood sampling. Peripheral blood mononuclear cells (PBMC) were obtained
by Ficoll gradient centrifugation from heparinized blood, and aliquots of 106 cells
were used for phenotyping studies. Sodium heparin anticoagulation and whole
blood were used for cytokine flow cytometry.
Antigen stimulation. The frequency of CMV-specific CD4 T cells was deter-
mined according to the previously described method (24). Briefly, whole blood
was dispensed into 15-ml propylene tubes with or without the addition of co-
stimulatory monoclonal antibodies anti-CD28 and anti-CD49d to a 1-g/ml final
concentration. CMV lysate (1/100 dilution) or staphylococcal enterotoxin B
(SEB; 200 ng/ml) was added, and an unstimulated sample was used as a negative
control. CMV lysate (strain AD169) was purchased from Microbix Biosystems,
Inc., and is inactivated by sonication. A negative control of mock-infected cell
lysate was used in each donor. SEB and Brefeldin A were purchased from Sigma,
United Kingdom. Culture tubes were incubated at 37°C for 6 h together with
Brefeldin A (10 g/ml) for the last 4 h. EDTA was then added to a 2 mM final
concentration for 15 min at room temperature. Red cells were then lysed, and
leukocytes were fixed by incubation with fluorescence-activated cell sorter
(FACS) lysing solution (Becton Dickinson, United Kingdom) for 10 min at room
temperature. Cells were washed in phosphate-buffered saline (PBS) containing
0.5% bovine serum albumin and 0.1% sodium azide and added to FACS per-
meabilization buffer for 10 min at room temperature. The cells then were washed
* Corresponding author. Mailing address: C.R. U.K. Institute for
Cancer Studies, Vincent Drive, Edgbaston, University of Birmingham,
Birmingham B15 2TA, United Kingdom. Phone: 44-121 414 2824. Fax:
44-121 414 4486. E-mail: p.moss@bham.ac.uk.
 Published ahead of print on 4 April 2007.
7759
in PBS with bovine serum albumin and sodium azide prior to immunofluorescent
staining.
Labeling with monoclonal antibodies and flow cytometric analysis. Cells were
incubated with directly conjugated monoclonal antibodies for 30 min at room
temperature in the dark. They were then washed and fixed in 1% paraformal-
dehyde in PBS, and flow cytometric analysis was performed by FACS. A mini-
mum of 50,000 CD4 cells was collected in each analysis. Cells were gated
initially on side scatter versus forward scatter to collect lymphocytes and then on
CD4 cells versus side scatter. Data were analyzed using WinMDI software and
are displayed as dot plots of cytokine expression versus CD69 fluorescence.
Monoclonal antibodies and antigens. The following monoclonal antibodies
were used in this study: anti-gamma interferon (anti-IFN-; fluorescein isothio-
cyanate [FITC] and phycoerythrin [PE]), anti-interleukin-2 (anti-IL-2; FITC and
PE), anti-tumor necrosis factor alpha (anti-TNF-; FITC and PE), mouse im-
munoglobulin G2a (IgG2a; FITC and PE), mouse IgG1 (FITC and PE), and
anti-CD49d and anti-CD28 were obtained from Becton-Dickinson Immunocy-
tometry Systems. Anti-CD4 (PE Texas Red [ECD] and PE-Cy5 [PC5]), anti-CD3
(PE), anti-CD69 (PC5), anti-CD57 (FITC and PE), anti-CD28 (FITC), anti-
CD45RO (FITC and PE), anti-CD45RA (FITC), anti-CD27 (FITC), anti-CD38
(FITC), anti-HLA-DR (FITC), and mouse IgG1 (ECD and tricolor [TC]) were
obtained from Coulter Immunology. Anti-CD28 (TC) and anti-CD8 (TC) were
from Caltag. Anti-CCR7 (FITC) was obtained from R&D Systems.
Statistical analysis. Intergroup comparisons were performed using the Mann-
Whitney U test. All P values were two-tailed and were modified according to the
Holm-Bonferroni correction. They were considered significant if the corrected P
value remained 0.05.
RESULTS
The CMV-specific CD4 T-cell response increases with age.
Cytokine flow cytometry (CFC) was used to determine the
CD4 T-cell response to CMV viral lysate in a cohort of 30
healthy donors aged up to 50 years (range, 22 to 50 years) and
40 healthy donors aged over 65 years (range, 65 to 84 years).
CMV-specific cells were clearly identified by production of
cytokine in response to antigen (Fig. 1A). A mock lysate was
used as a negative control in all donors, and negligible cytokine
secretion was observed in response to this agent (0.03% of
CD4 pool). Furthermore, no significant cytokine response to
CMV lysate was detected in eight CMV-seronegative donors
tested (0.05% of CD4 pool).
FIG. 1. The frequency of CMV-specific CD4 T cells is increased in elderly donors. Whole blood from CMV-seropositive donors was incubated
with CMV viral lysate at 37°C for 6 h or with mock lysate as a control. The blood was then lysed, fixed, permeabilized, and stained with monoclonal
antibodies. The frequency of the cells responsive to CMV was determined by the fraction of CD4 T cells which upregulated CD69 and expressed
detectable amounts of intracellular TNF-, IFN-, and IL-2. A. Representative flow cytometric profiles from a single elderly donor for the isotype
control (i) and IFN- (ii) and IL-2 (iii) cytokine responses to CMV lysate. B. The frequency of CMV-specific CD4 T cells in individual donors is
expressed as a percentage of the total CD4 T-cell pool and shown as a single data point. The mean value within the group is indicated as a
horizontal line. (i) The mean percentage of CMV-specific CD4 T cell producing IFN- was 2% in young donors (range, 0.4 to 5.78%) and 4.3%
in elderly donors (0.3 to 32%) (P  0.03). (ii) The mean percentage of CMV-specific CD4 T cells producing TNF- was 2.2% in young donors
(range, 0.51 to 4.7%) and 4.7% in elderly donors (0.3 to 16.7%) (P  0.08). (iii) The mean percentage of CMV-specific CD4 T cells producing
IL-2 was 1.1% in young donors (range, 0.1 to 4.8%) and 1.3% in elderly donors (0.26 to 4.9%) (P  0.9).
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High levels of CMV-specific CD4 T cells were detected by
IFN- or TNF- secretion in the elderly cohort. In eight do-
nors the CMV-specific CD4 T-cell response comprised over
10% of the CD4 T-cell pool, with a highest value of 32% in one
donor. The IFN- cytokine response averaged 2.32% (0.2 to
12.4%) in young donors and 5.92% (0.33 to 32.0%) in the
elderly group, which represents a significant increase with age
(P  0.03). Comparable values were observed for the TNF-
cytokine response, with averages of 2.2% (0.51 to 4.7%) and
4.7% (0.3 to 17%) in the young and elderly groups, respectively
(P  0.08) (Fig. 1B).
CMV-specific CD4 T cells in elderly donors show impaired
secretion of IL-2. In addition to production of antiviral and
proinflammatory cytokines as described above, IL-2 secretion
by CD4 T cells is important for promoting T-cell proliferation
and can be used as a surrogate marker for T helper function.
We thus measured the frequency of IL-2-producing CD4 T
cells in response to CMV lysate in our panel of young and
elderly donors. In contrast to the findings with the IFN- and
TNF- CFC assay, the IL-2 cytokine response did not increase
with age, with mean responses of only 1.1% (0.1 to 4.8%) and
1.3% (0.26 to 4.9%) in the younger and older cohorts, respec-
tively (P  0.9) (Fig. 1B). This observation was reflected in a
significant reduction in the ratio for IL-2 versus IFN- cytokine
production within CMV-specific CD4 T cells in association
with aging. The median value was 0.63 in the younger donors
but decreased to 0.37 in the elderly cohort (P 0.003) (Fig. 2).
Cytokine production from CMV-specific CD4 T cells in el-
derly donors is less dependent on costimulation. Costimula-
tory antibodies, such as anti-CD28 and anti-CD49d, are rou-
tinely used to maximize detection of the antigen-specific CD4
T-cell response in cytokine flow cytometry assays. CD28 is an
important costimulatory molecule on T cells, although expres-
sion is frequently lost on highly differentiated populations,
including CMV-specific T cells. CD49d is one component of
the 41 integrin. Previous work has shown that the use of
these agents increases detection of the CMV-specific CD4
T-cell response by up to threefold and that IL-2 production is
more dependent on costimulation than the IFN- response
(28).
The CMV-specific CD4 T-cell response, measured by IFN-
production in response to CMV lysate stimulation, was deter-
mined in both age cohorts in the presence or absence of co-
stimulatory antibodies. In a panel of 11 young donors, the
addition of costimulatory antibodies to the CFC assay resulted
in an increase in the detection of CMV-specific CD4 T cells in
all donors (Fig. 3A). In contrast, in 11 donors aged over 65
years, there was no increment in the CFC response with the
addition of costimulation (Fig. 3A). The increment in the num-
ber of CMV-specific T cells detected with the addition of
FIG. 2. The ratio of IL-2/IFN- production by CMV-specific CD4
T cells is decreased in elderly donors. Whole blood stimulation and
cytokine flow cytometry were used to determine IFN- and IL-2 pro-
duction in response to CMV viral lysate. PBMC were stimulated with
CMV lysate, and the percentage of cells which produced IL-2 or IFN-
was determined and expressed as a ratio (IL-2/IFN-). Data from each
donor are expressed as a single data point, with the median indicated
by a horizontal line. The median value was 0.63 in the young donors
and 0.37 in elderly donors (P  0.003).
FIG. 3. Influence of addition of costimulatory antibodies on de-
tection of CMV-specific CD4 T cells in young or elderly donors.
PBMC were stimulated with CMV lysate in the presence or absence
of costimulatory antibodies to CD28 or CD49d. A. Magnitude of
the CMV-specific CD4 T-cell response determined by CFC in the
presence or absence of costimulatory antibodies in 11 young (i) and
11 elderly (ii) donors. B. Mean ratio of CMV-specific CD4 T cells
detected in the presence or absence of costimulatory antibodies in
young or elderly donors. The mean ratio was 2.2 (range, 1.07 to
3.90) in young donors. In elderly donors the mean ratio was 1, with
a range of 0.40 to 1.48 (P  0.0002).
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costimulatory antibodies averaged 2.2-fold in young donors,
with no increase in elderly donors (P  0.0002) (Fig. 3B). This
independence of CMV-specific T cells in elderly donors from
the requirement for costimulation indicates that the activation
threshold of CMV-specific CD4 T cells in elderly donors is
reduced in comparison to younger donors. To verify that the
addition of costimulatory antibodies did not stimulate nonspe-
cific cytokine production, we also tested mock lysate responses
and CMV lysate responses (in CMV-seronegative donors) with
costimulation. In both sets of control experiments we did not
observe an increment in the response from the background
levels observed without costimulation (data not shown).
CMV-specific CD4 T cells are highly differentiated effector
memory cells. It was also necessary to characterize the cell
membrane phenotype of CD4 T cells specific for CMV in
young and elderly donors. As before, cells were stimulated with
CMV lysate and then stained for surface expression of
CD45RA, CD45RO, CD27, CD28, CCR7, and CD62 ligand
(CD62L). After washing, cytoplasmic staining for IFN- was
performed. Figure 4 describes the observed phenotypes in
young and elderly donors. The expression of CD45 isoforms
was generally biased towards CD45RO (approximately 80%)
in both young and elderly donors (Fig. 4A to D), indicating an
effector memory phenotype. The presence of a small but sig-
nificant CD45RAhigh CD4 T-cell population was demonstrable
in many donors, suggesting a revertant memory phenotype,
although this did not appear to accumulate particularly with
age (Fig. 4E). CD27 expression was lower than CD28 expres-
sion on virus-specific CD4 T cells (Fig. 4A to D), with a trend
towards further reduction in elderly donors (Fig. 4E). In vir-
tually all donors tested, the CMV-specific CD4 response was
uniformly very low for CCR7 and CD62L expression (data not
shown), although it is possible that CD62L may have been
downregulated following stimulation.
CMV seropositivity is associated with a significant alter-
ation in the phenotype of the CD4 T-cell repertoire. As the
CD4 T-cell response to CMV accumulates with age, it was felt
important to assess the contribution of CMV carriage to the
phenotype of the total CD4 T-cell repertoire. The expression
of eight phenotypic markers was therefore determined on CD4
T cells from 10 CMV-seropositive donors aged over 65 years
and a further 10 age-matched CMV-seronegative donors (Fig.
5). The CD45RO isoform is a marker of antigen experience,
and the percentage of CD45RO CD4 T cells was significantly
increased in CMV-seropositive donors in comparison to the
CMV-seronegative cohort (53 versus 43%; P  0.012). A re-
duction was seen in the CD45RA CD4 T-cell population in
CMV-seropositive donors, although this did not reach statisti-
cal significance (45 versus 53%; P 0.07). CD27 and CD28 are
costimulatory molecules but support T-cell expansion through
different mechanisms. CD27 does not affect cell cycle activity
but supports survival of activated T cells (11). CD27 expression
was markedly reduced on CD4 T-cell populations in CMV-
seropositive donors (77 versus 94%; P  0.00016). In addition,
in CMV-seropositive donors 14% of CD4 T cells had lost
expression of the major costimulatory molecule CD28,
whereas this population represented less than 1% of the CD4
T-cell pool in CMV-seronegative donors.
CD57, CD38, and HLA-DR are expressed following T-cell
activation, and CMV seropositivity was associated with a dra-
FIG. 4. Phenotypic analyses of CMV-specific CD4 T-cell responses in young and elderly asymptomatic virus carriers. PBMC from donors were
stimulated with CMV lysate and then surface stained with monoclonal antibodies specific for each of the phenotypic markers shown, followed by
cytoplasmic IFN- staining. Representative data are shown for two young (A and B) and two elderly (C and D) donors. (E) Summarized data
showing CD45RA, CD45RO, CD27, and CD28 expression in all young and elderly donors tested are also shown. The y axis represents the percent
of CMV-specific CD4 T cells expressing each marker.
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matic increase in the expression of CD57 CD4 T cells from
0.9% in the CMV-seronegative donors to 10.6% in the CMV-
seropositive cohort (P  0.0006). The function of CD57 CD4
T cells remains under investigation, although such populations
do not support immunoglobulin production (2) but can exhibit
cytotoxic activity (26). The HLA-DR CD4 T-cell subset was
increased from 8.3% to 13% in CMV-seropositive donors,
although this did not reach statistical significance.
CCR7 expression is present on naı¨ve and central memory T
cells but is absent on effector memory populations (23). The
percentage of CCR7 CD4 T cells was significantly decreased
in CMV-seropositive donors (69 versus 86%; P  0.0015) and
likely reflects an accumulation of effector memory cells.
CD4 T cells from CMV-seropositive elderly donors show
comparable IL-2 responses to superantigen stimulation. The
alterations in the phenotype of the CD4 T-cell repertoire as-
sociated with CMV seropositivity might be associated with
impairment of the CD4 T-cell response to heterologous anti-
gen in these donors. SEB superantigen was used as a source of
antigen to stimulate CD4 T cells from CMV-seropositive or
CMV-seronegative donors in vitro, and the response was mea-
sured by cytokine flow cytometry (Table 1). Our primary hy-
pothesis was that we might expect a difference in the IFN-,
TNF-, and IL-2 responses to such an antigen. The mean value
of the IFN- cytokine response to SEB was 5.6% in CMV-
seropositive donors compared to 3.8% in CMV-seronegative
donors, although this did not reach significance after Holm-
Bonferroni correction for multiple testing (P  0.03). Sub-
group analysis of dual-cytokine-producing cells revealed that
the number of cells with a combined IFN- IL-2 cytokine
phenotype was increased in CMV-seropositive donors (mean,
3.6 versus 1.6%), but this result did not reach statistical signif-
icance. Polarized IFN- secretion is characteristic of effector/
memory Th1 CD4 T cells, and this result is likely to reflect a
trend towards the accumulation of this subset in CMV-sero-
positive donors. The number of CD4 T cells that produced
IL-2 in response to SEB was reduced by 33% in CMV-sero-
positive compared to CMV-seronegative donors (mean, 4.1
versus 6%, respectively). Although this did not reach statistical
significance, this suggests a reduction in the number of central
memory and naı¨ve T cells in CMV-seropositive donors and is
supported by a nonsignificant reduction in the percentage of T
cells with an IFN- IL-2 cytokine phenotype in response to
SEB in these donors (mean, 2.5 versus 3.9%).
DISCUSSION
Infectious disease remains a major cause of morbidity and
mortality in all populations, and the elderly are at particular
risk of clinical disease (8). This has been attributed to a num-
ber of findings, of which a functional impairment of the im-
mune system termed immune senescence is believed to be a
major cause. Immune senescence is characterized by features
such as reduction in the number of naive T cells and an accu-
mulation of memory cells (1). The combination of features
such as an inverted CD4/CD8 ratio and reduced proliferative
response to mitogen has been term the immune risk phenotype
and has been directly associated with impaired survival in co-
hort studies of healthy elderly donors (20, 29). Primary CMV
infection is usually silent, but the virus is not cleared from the
host and enters a state of viral latency. The majority of indi-
viduals over the age of 65 years are CMV seropositive, al-
though CMV seropositivity is generally not considered to be of
clinical significance in the immunocompetent host.
However, the potential association between CMV infection
and immune senescence is coming under increasing scrutiny.
CMV seropositivity is associated with the development of the
immune risk phenotype (21), and an impaired immune re-
sponse to influenza vaccination is observed in CMV-seroposi-
tive donors (25). In contrast to the immune response to most
infections, the CD8 T-cell immune response to CMV increases
markedly with age, such that over 40% of the CD8 T-cell pool
may comprise CMV-specific T cells in some donors (15). It is
possible that the development of such large memory T-cell
expansions may be associated with an impairment of the im-
mune response to heterologous agents. Age-related CD8 T-
TABLE 1. Comparative analysis of cytokine production in CD4 T
cells following SEB stimulation in elderly donors grouped
according to CMV serostatus
Cytokine profile
Mean (CI) cytokine production ina:
P valueCMV seropositive
(n  15)
CMV seronegative
(n  15)
IFN- 5.6 (1.1–11) 3.8 (1.4–8.3) NS
TNF- 6.9 (0.75–15) 8.0 (1.1–18) NS
IL-2 4.1 (1.23–7.9) 6 (1.8–10) NS
IFN- IL-2 1.6 (0.92–2.8) 2.2 (0.5–7.2) NS
IFN- IL-2 3.6 (1.1–8.1) 1.6 (0.68–4.1) NS
IFN- IL-2 2.5 (0.74–3.6) 3.9 (1.1–10.3) NS
a All data were gated on CD3 CD4 events. CI, 95% confidence interval.
FIG. 5. Expression of differentiation and activation markers on pe-
ripheral blood CD4 T cells of healthy CMV-seropositive and -sero-
negative donors. PBMC from CMV-seronegative (n  10) and CMV-
seropositive (n  10) donors aged 	65 years were stained with FITC,
PE, and PC5-conjugated MAb. CD4 CD3 lymphocytes were gated
and analyzed for the expression of a range of phenotypic markers on
the third color. The mean percentages of CD4 T cells expressing individ-
ual phenotypic markers in CMV-seronegative or CMV-seropositive do-
nors were as follows: CD45RA (53 and 45%, respectively; P  0.0.07);
CD45R0 (43 and 53%; P  0.012) CD27 (94 and 77%; P  0.00016);
CD28 (99 and 86%; P  0.00014); CD57 (0.92 and 11%; P  0.0006);
CD38 (44 and 38%; P 0.3); HLA-DR (8.3 and 13%; P 0.1); CCR7
(86 and 69%; P  0.0015).
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cell clonal expansions in mice are associated with an impaired
immune response to viral infection, due to constriction of the
CD8 T-cell repertoire (17). However, the potential importance
of the CMV-specific CD4 T-cell immune response in relation
to immune function during aging has received less attention.
Here we show that in CMV-seropositive individuals there is
an accumulation of CMV-specific CD4 T cells in association
with aging. This supports recent data showing that the percent-
age of CMV-specific CD4 T cells increases with age, whereas
other virus-specific CD4 T-cell responses do not (9). The cy-
tokine flow cytometry assay revealed that the CMV-specific
immune response to viral lysate constitutes nearly 6% of the
CD4 T-cell repertoire in the elderly, a frequency that is con-
siderably greater than for other pathogen-specific immune re-
sponses. Nevertheless, indirect evidence suggests that this fre-
quency is likely to be a significant underestimate of the total
CMV-specific CD4 T-cell response. Although lysate of CMV-
infected cells is widely used as an antigenic source for the
identification of CMV-specific CD4 T cells, the full comple-
ment of viral proteins may not be evenly presented by antigen-
presenting cells due to competition for HLA class II binding.
There may also be CMV-specific CD4 T cells that go undetec-
ted due to their inability to produce cytokines during in vitro
analysis, and this has been shown repeatedly in the detection of
CMV-specific CD8 T cells using major histocompatibility com-
plex class I peptide tetramers (15).
CMV-specific cytotoxic T lymphocytes in elderly donors
demonstrated lower levels of IL-2 production, which is char-
acteristic of CD4 T cells with a low activation threshold (12, 18,
28). Production of IL-2 may be necessary in states of high
antigen load or inflammation in situations requiring expansion
of effector T cells. CMV-specific CD4 T cells are characterized
by a CD28 CD57 effector memory phenotype, and an
IFN- IL-2 cytokine profile is typical of this subset (23).
Murine data have shown that a memory CD4 T-cell subset with
predominant expression of IL-2 is preferentially located within
lymphoid tissue, and examination of the frequency and cyto-
kine production of CMV-specific CD4 T cells within secondary
lymphoid tissue will be of interest (22).
The functional properties of the CMV-specific CD4 T-cell
response show significant differences between young and el-
derly donors. The CMV-specific CD4 T-cell response exhibits
heterogeneity in the activation threshold based on the require-
ment for costimulation in the form of antibodies to CD28 or
CD49d or activation of antigen-presenting cells by agents such
as TNF- (28). Such differences in threshold can be found
within a single clonotype and appear to be independent of
T-cell receptor stimulation and consistent with an intrinsic
activation threshold that is downstream of the T-cell receptor
(6). The young donors in our study exhibited this phenomenon,
and the addition of costimulatory antibodies increased the
magnitude of the detected CMV-specific immune response by
a factor of 1.1- to 3.7-fold. In contrast, costimulation did not
increase detection of the CMV-specific CD4 T-cell response in
elderly donors, indicating that cells have a lower threshold
level for activation.
Many CMV-specific CD4 T cells lose expression of CD28,
and anti-CD28 antibody is therefore unlikely to act as a co-
stimulatory stimulus to this population. However, CD28
CMV-specific CD4 T cells are also seen in considerable num-
bers in young donors (27). There was no correlation between
the magnitude of the CMV-specific response and response to
costimulation, suggesting that maintenance, rather than expan-
sion, of CD4 T-cell clones is associated with an alteration in
signaling threshold.
The factors that determine the threshold of an antigen-
specific response are uncertain, but repeated episodes of anti-
genic stimulation may be one factor. CMV latency is associated
with episodes of subclinical viremia (19), and it is likely that
CMV carriage for many decades exposes the donor to inter-
mittent viral reactivation with consequent repeated activation
of T-cell immunity. The physiological significance of this
change in activation threshold is uncertain, but T cells with
lower thresholds for activation are more likely to be able to
control viral reactivation in the setting of minimal inflamma-
tion and low antigen load. They may thus be well adapted to
control low levels of CMV reactivation with minimal bystander
damage and exhibit a form of pathogen control based on a high
cytotoxic T-lymphocyte–low-antigen-load model. It has also
been shown by others that CMV-specific CD4 T cells are
driven to replicative exhaustion in elderly CMV-seropositive
hosts (9), although incidents of virus-associated disease in such
patients do not occur. Whether this becomes problematic at a
later stage for such individuals remains unknown.
The phenotype of CMV-specific CD4 T cells indicated that
cells had an effector memory profile with almost complete loss
of CCR7 and CD62L. Most cells expressed the memory
marker CD45RO, but a significant minority had a revertant
phenotype with high-level expression of CD45RA although, in
contrast to CD8, this population did not increase with age.
The proportion of cells which had lost expression of CD27 and
CD28 showed an increase with age, in agreement with a pre-
vious report (9). The accumulation of effector memory CMV-
specific CD4 T cells was reflected in a marked alteration in
the global CD4 T-cell repertoire in elderly donors. CD27
and CD28 CD4 T-cell populations were increased from 6%
and 1% of the CD4 T-cell pool, respectively, in CMV-seroneg-
ative donors to over 23% and 13% in the CMV-seropositive
cohort (4). It is likely that most of the CD4 CD28 CD4
T-cell population has specificity for CMV, as documented in a
recent report (27). CD57 expression is associated with a highly
differentiated cytotoxic phenotype (18) and increases markedly
from less than 1% of the CD4 T-cell repertoire to over 10% in
CMV-seropositive donors. These data suggest that CMV-spe-
cific CD4 T cells may represent up to 10% of the T-cell pool in
healthy elderly donors, although it is also possible that CD27
and CD28 loss is induced on T cells which are not specific for
CMV peptides due to cytokine-mediated effects (9). An accu-
mulation of CD4 T cells expressing the activation marker
HLA-DR or CD45RO, the CD45 isoform expressed on anti-
gen-experienced T cells, is also observed in association with
CMV seropositivity. Such an expansion of memory T cells may
impair the number of naı¨ve T cells within the CD4 T-cell
repertoire, and this may be reflected in the 17% decrease in
the percentage of CD4 CCR7 T cells in CMV-seropositive
donors.
CMV-specific CD8 T cells are markedly expanded in elderly
donors, and it may be possible that the CMV-specific CD4 T
cells are providing help for CD8 T-cell expansion.
No correlation was observed between the magnitude of
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CMV-specific CD8 and CD4 immune responses in individual
donors in our study (data not shown). However, an association
cannot be formally ruled out, because the CD8 data were
derived using a panel of tetramers that covers common but,
importantly, not all HLA class I types (15).
CMV seropositivity is associated with the accumulation of
large numbers of virus-specific CD4 T cells and a profound
alteration of the global T-cell repertoire. These features may
impair the ability of the immune response to respond to het-
erologous antigen, and this was assessed by analysis of the
response of CD4 T cells to stimulation in vitro with superan-
tigen. Among CMV-seropositive donors, a nonsignificant re-
duction was observed in the percentage of T cells that pro-
duced IL-2 in response to superantigen, and while further
studies are required this may reflect a reduction in the naı¨ve
and central memory CD4 T cells in CMV-seropositive donors.
CMV infection in immunocompetent donors has generally
been regarded as being of negligible consequence for the
health of the host, but accumulating data indicate that this may
be a naı¨ve assumption. Efforts to control the spread of CMV
infection or to limit levels of CMV viremia within an infected
host may serve to protect the immune system from the accu-
mulation of potentially crippling levels of cellular immune re-
sponses.
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